Tango Therapeutics, Inc. (TNGX): Total Liabilities
$52.51M
As of 2025-12-31
$49.35M
As of 2026-06-30
-34.5%
3-year compound annual growth
-20.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.51M | -55.1% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $116.97M | -21.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $149.46M | -20.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $186.99M | +20.3% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $155.41M | -7.9% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $168.65M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
Compare TNGX, NUVB, FBIO, DERM side by side · Screen every company in Pharmaceutical Preparations ↗